UY33652A - Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar) - Google Patents

Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar)

Info

Publication number
UY33652A
UY33652A UY33652A UY33652A UY33652A UY 33652 A UY33652 A UY 33652A UY 33652 A UY33652 A UY 33652A UY 33652 A UY33652 A UY 33652A UY 33652 A UY33652 A UY 33652A
Authority
UY
Uruguay
Prior art keywords
interleucine
antibodies
receiver
formulations containing
containing anti
Prior art date
Application number
UY33652A
Other languages
English (en)
Inventor
Dix Daniel
Tang Xiaolin
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of UY33652A publication Critical patent/UY33652A/es

Links

Abstract

La presente invención proporciona formulaciones farmacéuticas que comprenden un anticuerpo humano que se une específicamente al receptor de interleucina-4 humano (hIL-4R). Las formulaciones pueden contener, además de un anticuerpo anti-hlL-4R, al menos un aminoácido, al menos un carbohidrato, o al menos un tensoactivo no iónico. Las formulaciones farmacéuticas de la presente invención exhiben un grado sustancial de estabilidad del anticuerpo d espués del almacenamiento durante varios meses.
UY33652A 2010-10-06 2011-10-06 Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar) UY33652A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39028310P 2010-10-06 2010-10-06

Publications (1)

Publication Number Publication Date
UY33652A true UY33652A (es) 2012-04-30

Family

ID=45995014

Family Applications (1)

Application Number Title Priority Date Filing Date
UY33652A UY33652A (es) 2010-10-06 2011-10-06 Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar)

Country Status (13)

Country Link
AR (1) AR083338A1 (es)
DK (2) DK2624865T3 (es)
ES (2) ES2820246T3 (es)
HK (1) HK1258305A1 (es)
HR (1) HRP20181822T1 (es)
HU (1) HUE052089T2 (es)
LT (1) LT2624865T (es)
PT (1) PT3354280T (es)
RS (1) RS57850B1 (es)
SI (1) SI2624865T1 (es)
TW (7) TWI679988B (es)
UA (1) UA111731C2 (es)
UY (1) UY33652A (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110624107A (zh) 2012-08-21 2019-12-31 赛诺菲生物技术公司 通过施用il-4r拮抗剂治疗或预防哮喘的方法
TWI707694B (zh) * 2013-06-21 2020-10-21 法商賽諾菲生物技術公司 Il-4r拮抗劑用於製造治療鼻息肉症的藥物之用途
PL3010539T3 (pl) * 2013-06-21 2020-01-31 Sanofi Biotechnology Sposoby leczenia polipowatości nosa przez podawanie antagonisty il-4r
KR20170081262A (ko) 2014-11-14 2017-07-11 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한, 비용종을 동반한 만성 부비동염의 치료 방법
US11034768B2 (en) 2017-10-30 2021-06-15 Sanofi Biotechnology Methods for treating or preventing asthma by administering an IL-4R antagonist

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
ES2332082B1 (es) * 2008-07-24 2010-10-26 Consejo Superior De Investigaciones Cientificas (Csic) 45% Sistema de alineacion de patrones en un sustrato mediante litografia por estencil.
JP4487083B2 (ja) * 2008-09-10 2010-06-23 日本エクスラン工業株式会社 架橋アクリレート系繊維およびその製造方法
CA2754528A1 (en) * 2009-03-06 2010-09-10 Genetech, Inc. Antibody formulation

Also Published As

Publication number Publication date
DK2624865T3 (en) 2018-10-22
RS57850B1 (sr) 2018-12-31
TW201221141A (en) 2012-06-01
TW202320851A (zh) 2023-06-01
HRP20181822T1 (hr) 2018-12-28
AR083338A1 (es) 2013-02-21
HUE052089T2 (hu) 2021-04-28
TW201924718A (zh) 2019-07-01
ES2687813T3 (es) 2018-10-29
TW201542229A (zh) 2015-11-16
TWI679988B (zh) 2019-12-21
LT2624865T (lt) 2018-10-25
ES2820246T3 (es) 2021-04-20
DK3354280T3 (da) 2020-09-28
HK1258305A1 (zh) 2019-11-08
TWI498121B (zh) 2015-09-01
SI2624865T1 (sl) 2018-10-30
UA111731C2 (uk) 2016-06-10
TWI782325B (zh) 2022-11-01
TW202026011A (zh) 2020-07-16
TWI568445B (zh) 2017-02-01
TWI718890B (zh) 2021-02-11
PT3354280T (pt) 2020-09-01
TW201716086A (zh) 2017-05-16
TW202102262A (zh) 2021-01-16
TWI690329B (zh) 2020-04-11

Similar Documents

Publication Publication Date Title
ECSP12012092A (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleuquina-6 (il-6r)
CY1121233T1 (el) Σταθεροποιημενα σκευασματα που περιεχουν αντισωματα καtα του υποδοχεα iντερλευκinης-4(ιl-4r)
UY33515A (es) Formulaciones estabilizadas que contienen anticuerpos anti-ngf
CO2019011021A2 (es) Formulacion estable de anticuerpos
CY1126062T1 (el) Σταθερη φαρμακοτεχνικη μορφη anti-ifnar1
PH12014501628B1 (en) Stabilized formulations containing anti-ang2 antibodies
BR112018067792A2 (pt) preparação contendo o anticorpo
MY157772A (en) Antibody formulation
CR11005A (es) Formulaciones estables de anticuerpos
CR10555A (es) Vacunas para malaria
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
UY33652A (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4(il-ar)
MX2009005414A (es) Formulaciones liquidas de anticuerpo antirrabico.
MA37645A2 (fr) Formulations stabilisées contenant des anticorps anti-dll4
CO2021011648A2 (es) Formulaciones estabilizadas que contienen anticuerpos anti-il-33
GT201300058A (es) Composiciones de anticuerpos anti-vegfr-3
TN2012000342A1 (en) Stabilized formulations containing anti-interleukin-6 receptor (il-6r) antibodies
EA202090016A3 (ru) Стабилизированные композиции, содержащие антитела к рецептору интерлейкина-4 (il-4r)
TH175929A (th) สูตรตำรับของแอนติบอดี้ (Antibody Formulation)
TH125691A (th) สูตรของแอนตี้บอดี้